Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 6593232, 7 pages
http://dx.doi.org/10.1155/2016/6593232
Research Article

Evaluation of Two Methods for Determination of CD64 as a Diagnostic Marker of Infection in Critically Ill Adults

1Intensive Care Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
3Clinical Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
4Division of Medical Practice, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
5Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA

Received 25 July 2016; Revised 13 October 2016; Accepted 15 November 2016

Academic Editor: Anastasia Kotanidou

Copyright © 2016 Thiago Zinsly Sampaio Camargo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. Diagnostic markers of infection have had little innovation over the last few decades. CD64, a marker expressed on the surface of neutrophils, may have utility for this purpose. Methods. This study was conducted in an adult intensive care unit (ICU) in São Paulo, Brazil, with 89 patients. We evaluated CD64 in patients with documented or clinically diagnosed infection (infection group) and controls (patients without any evidence of infection) by two different methodologies: method #1, an in house assay, and method #2, the commercial kit Leuko64 (Trillium Diagnostics). Results. CD64 displayed good discriminating power with a 91.2% sensitivity (95% CI 90.7–91.6%) for detecting infection. The commercial kit (Leuko64) demonstrated higher specificity (87.3%) compared with method #1 as well as better accuracy (88.8%). Conclusions. CD64 seems to be a promising marker of infection in the intensive care setting, with Leuko64 showing a slight advantage.